Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Regeneron Pharmaceuticals Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Accounts payable 497,300 561,700 671,300 606,600 536,600 547,300 599,500 589,200 535,600 534,200 470,300 564,000 427,000 476,000 542,900 475,500 443,100 380,100 347,800 418,100 335,600 244,000 239,600
Accrued expenses and other current liabilities 2,536,500 2,360,900 2,392,900 2,357,900 2,644,700 2,176,000 2,074,300 2,074,200 1,796,400 1,933,400 2,046,000 2,206,800 2,061,000 2,018,000 1,492,200 1,644,200 1,399,900 1,360,800 1,228,200 1,086,800 821,100 876,700 741,100
Debt 1,500,000
Finance lease liabilities, current portion 719,700 719,000 718,400 717,800
Deferred revenue 627,200 586,000 516,700 458,900 417,300 381,100 426,300 477,900 547,200 566,300 491,300 442,000 507,800 520,000 464,900 577,700 494,800 461,500 479,200 591,700 608,700 592,400 530,700
Current liabilities 3,661,000 3,508,600 3,580,900 3,423,400 3,598,600 3,104,400 3,100,100 3,141,300 2,879,200 3,033,900 3,007,600 3,932,500 3,714,800 3,732,400 3,217,800 2,697,400 2,337,800 3,702,400 2,055,200 2,096,600 1,765,400 1,713,100 1,511,400
Long-term debt 1,984,000 1,983,600 1,983,300 1,982,900 1,982,600 1,982,200 1,981,800 1,981,400 1,981,100 1,980,700 1,980,400 1,980,000 1,979,600 1,979,200 1,978,900 1,978,500 1,978,300
Finance lease liabilities, excluding current portion 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 720,000 717,200 716,500 715,900 715,200 713,900 712,700 711,300 709,900
Deferred revenue 207,400 205,600 185,800 126,700 125,300 116,200 85,500 69,800 60,100 58,700 33,500 73,300 56,500 50,700 27,000 57,800 104,900 104,800 82,100 619,000 683,800 725,400 812,500
Other noncurrent liabilities 1,543,600 1,463,200 908,500 854,100 832,400 716,800 677,300 638,000 598,600 724,700 692,500 680,200 662,600 596,300 571,500 687,100 821,000 848,200 772,000 286,000 273,000 267,900 376,300
Noncurrent liabilities 4,455,000 4,372,400 3,797,600 3,683,700 3,660,300 3,535,200 3,464,600 3,409,200 3,359,800 3,484,100 3,426,400 2,733,500 2,698,700 2,626,200 2,577,400 3,440,600 3,620,700 1,668,900 1,569,300 1,618,900 1,669,500 1,704,600 1,898,700
Total liabilities 8,116,000 7,881,000 7,378,500 7,107,100 7,258,900 6,639,600 6,564,700 6,550,500 6,239,000 6,518,000 6,434,000 6,666,000 6,413,500 6,358,600 5,795,200 6,138,000 5,958,500 5,371,300 3,624,500 3,715,500 3,434,900 3,417,700 3,410,100
Preferred Stock, par value $.01 per share; shares issued and outstanding: none
Class A Stock, convertible, par value $.001 per share
Common Stock, par value $.001 per share 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100
Additional paid-in capital 12,702,800 12,316,900 11,942,600 11,354,000 11,251,500 10,888,500 10,597,700 9,949,300 9,518,200 9,120,200 8,754,100 8,087,500 7,919,300 7,225,800 6,887,800 6,716,200 6,592,800 6,263,000 5,211,400 4,428,600 4,388,400 4,263,600 4,160,900
Retained earnings 30,755,200 29,414,600 27,982,300 27,260,300 26,100,700 25,092,900 24,124,500 23,306,700 22,109,600 20,793,900 19,941,800 18,968,300 16,739,300 15,107,100 12,008,200 10,893,000 9,743,800 8,901,700 8,004,400 7,379,800 6,587,800 5,918,200 5,725,100
Accumulated other comprehensive income (loss) 60,200 (69,900) (77,200) (80,900) (176,800) (197,700) (181,600) (238,800) (275,100) (223,800) (170,100) (26,200) 9,500 15,700 16,200 29,300 30,800 35,500 (9,100) 21,100 16,500 15,800 2,800
Treasury Stock, at cost (14,192,400) (13,455,900) (12,856,700) (12,560,400) (12,271,100) (11,765,900) (11,045,500) (10,353,300) (9,914,000) (9,002,600) (8,611,200) (8,260,900) (7,410,200) (7,221,400) (6,935,300) (6,613,300) (6,242,000) (6,142,900) (1,073,800) (739,900) (488,400) (441,800) (444,200)
Stockholders’ equity 29,325,900 28,205,800 26,991,100 25,973,100 24,904,400 24,017,900 23,495,200 22,664,000 21,438,800 20,687,800 19,914,700 18,768,800 17,258,000 15,127,300 11,977,000 11,025,300 10,125,500 9,057,400 12,133,000 11,089,700 10,504,400 9,755,900 9,444,700
Total liabilities and stockholders’ equity 37,441,900 36,086,800 34,369,600 33,080,200 32,163,300 30,657,500 30,059,900 29,214,500 27,677,800 27,205,800 26,348,700 25,434,800 23,671,500 21,485,900 17,772,200 17,163,300 16,084,000 14,428,700 15,757,500 14,805,200 13,939,300 13,173,600 12,854,800

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Regeneron Pharmaceuticals Inc. current liabilities decreased from Q1 2024 to Q2 2024 but then increased from Q2 2024 to Q3 2024 exceeding Q1 2024 level.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc. noncurrent liabilities increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Regeneron Pharmaceuticals Inc. total liabilities increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Regeneron Pharmaceuticals Inc. stockholders’ equity increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.